New 'Living Drug' trial offers hope for tough blood cancers
NCT ID NCT07162571
Summary
This early-stage study is testing a new type of personalized cell therapy for adults whose leukemia or lymphoma has returned or hasn't responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their cancer, then infuse them back. The main goals are to see if this approach is safe and if it can shrink or eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Dermatology
Minsk, 220087, Belarus
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.